A Phase I, Single-Arm, Single-Center Study to Investigate Safety and Reactogenicity of Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b in Healthy Children Aged 16 - 20 Months and Infants Aged 2 - 4 Months.

Trial Profile

A Phase I, Single-Arm, Single-Center Study to Investigate Safety and Reactogenicity of Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b in Healthy Children Aged 16 - 20 Months and Infants Aged 2 - 4 Months.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs TAK 816 (Primary)
  • Indications Haemophilus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Feb 2012 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top